A clinical trial involving semaglutide was updated on October 8, 2026. The study, titled "Probiotics in Obese Patients Treated With Semaglutide," is registered under identifier NCT07847593.
Its current status is listed as completed. The trial phase is designated as not applicable (NA), indicating it did not follow the standard phase classification used for drug trials.
The study examined the use of probiotics in obese patients who were being treated with semaglutide. No specific outcomes, findings, or results have been reported in the available event data.
This update reflects only a change in the trial's status on the registry. It does not indicate what conclusions, if any, were drawn from the study. Readers should consult the original registry listing for further procedural details, including enrollment information and study design, as those specifics were not included in this update.
For more background on semaglutide, including its approved uses and general information, readers can refer to the compound overview.